Integrin inhibitors – PharmaLive

AbbVie Makes Moves to Increase Profits in 2022

AbbVie, Blockbusters, Expirations, FDA, Integrin inhibitors, Janus Kinase (JAK) Inhibitors, Patents, Profit, Quarterly results, U.S. Securities and Exchange Commission (SEC)

Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line.

February 25, 2022/by BioSpace

Research Roundup: Regrowing Nerve Cells in Spinal Cord Injuries and More

Breast Cancer, Cancer Cell, Cells, Central Nervous System, COVID-19 Vaccines, DNA, Glaucoma, Integrin inhibitors, Mammalian, Nanoparticles, Nerve Cells, Neurons, Northwestern University, Pregnancies, Spinal Cord, UC Berkeley, Washington University School of Medicine in St. Louis

Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.

October 22, 2021/by BioSpace

Pliant Inks Deal with Novartis on Liver Disease NASH

Business, Deals, High Cholesterol, Integrin inhibitors, Liver Disease, Liver fibrosis, Nonalcoholic Steatohepatitis (NASH), Obesity, TGF-Beta Inhibitors, Type 2 Diabetes

Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

October 23, 2019/by BioSpace

Morphic and Janssen Strike Potential $750 Million Deal

Autoimmune Diseases, Business, Collaborations, Deals, Drug Discovery, Fibrosis, Fibrotic Diseases, Immuno-oncology, Integrin inhibitors, Integrins

Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.

February 21, 2019/by BioSpace